T3 Pharma Nears The Clinic With Live Bacteria To Treat Cancer
Five-Year-Old Swiss Biotech Raises CHF25m To Pursue Novel Approach
Using live bacteria modified to deliver specific proteins to treat cancer is to be explored by the Swiss start-up, T3 Pharmaceuticals, which has garnered a large third round of funding from a European corporate VC, institutional and private investors, to advance its lead candidate into clinical trials.
You may also be interested in...
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.
Boehringer Ingelheim’s sales were driven by Jardiance and Ofev in the first half of 2020, with contract manufacturing contributing with a 16% increase in sales; more details from the EMPEROR-Reduced Phase III study in heart failure are expected at this month’s European College of Cardiology meeting.